Reactions: Alzheimer's drug donanemab shows positive results in phase III trial, says drugmaker Eli Lilly
A press release from Eli Lilly claims that its antibody treatment, donanemab, significantly slowed cognitive and functional decline in a phase 3 study of early-stage Alzheimer's disease. The results have not yet been published in a scientific journal.
0